How long should a BPC-157 dosing cycle last before stopping
500K people track their GLP-1 with MeAgain, and the app has a 4.8-star App Store rating across 25K ratings and is available on iPhone and Android
One major challenge is the accessibility and affordability of these services, which often require the involvement of healthcare professionals like dietitians, whose services may not be covered by insurance
References The DREAMS-3 Phase III clinical study of Masdutide, a head-to-head semaglutide trial, achieved its primary endpoint in dual efficacy in reducing blood sugar and weight, 28 Oct 2025, Innovent Biologics, A Study Comparing IBI362 vs Semaglutide in Chinese Adults with Early Type 2 Diabetes and Obesity, ClinicalTrials.gov ID NCT06184568, Ji L, et al, Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial